Physician profile
Robert Okerblom
NPI 1942358643
$13,492.82
in general payments reported to CMS, 2019-2025
55 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,397 · 2020: $320 · 2021: $2,303 · 2022: $2,371 · 2023: $2,185 · 2024: $1,907 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,102.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,944.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $1,631.93 | 2021-2025 | |
| Novo Nordisk INC | $1,191.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,104.06 | 2019-2025 | |
| Lilly USA, LLC | $1,057.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $845.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $745.42 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $679.80 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $579.98 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $413.73 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $328.40 | 2019-2022 | |
| Astellas Pharma US INC | $317.34 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $235.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $228.20 | 2019-2024 | Verquvo |
| Idorsia Pharmaceuticals US INC | $180.07 | 2023 | Quviviq |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Okerblom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.